Jörg Thomas Hartmann, MD

home / authors / jörg-thomas-hartmann-md

Articles

UFT/Leucovorin Plus Weekly Paclitaxel in the Treatment of Solid Tumors

Carsten Bokemeyer, MD;Jörg Thomas Hartmann, MD;Frank Mayer, MD;Lothar Kanz, MD;Joachim Von Pawel, MD;Gunther Derigs, MD;Michael Schröder, MD

October 1st 2000

The palliation of symptoms and improvement of quality of life are important aspects of therapy in patients with incurable metastatic cancer. This article describes the preliminary results of a phase I study of uracil and tegafur, an orally available fluorouracil (5-FU) derivative combined with oral leucovorin plus weekly intravenous paclitaxel.

UFT/Calcium Folinate Plus Weekly Paclitaxel for Solid Tumors

Carsten Bokemeyer, MD;Jörg Thomas Hartmann, MD;Christian Kollmannsberger, MD;Frank Mayer, MD;Lothar Kanz, MD

July 1st 1999

Since cancer is incurable in many patients, palliation of symptoms and quality-of-life issues are important aspects of therapy. Uracil and tegafur (UFT) plus calcium folinate are the components of the oral agent known